BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 8916314)

  • 41. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
    Al Bahar S; Pandita R; Bavishi K; Savani B
    Neoplasma; 1999; 46(1):61-5. PubMed ID: 10355536
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Results of therapy with high-dose cytosine arabinoside].
    Pralle H; Breithaupt H
    Onkologie; 1985 Feb; 8(1):48, 50-2. PubMed ID: 3885122
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral idarubicin in combination with cytosine-arabinoside in previously untreated patients with acute non-lymphocytic leukemia.
    Falkson G; Coccia-Portugal MA; Vorobiof DA; Terblanche AP; Dreyer R
    Am J Clin Oncol; 1986 Aug; 9(4):311-4. PubMed ID: 3463190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
    Garcia-Manero G; Faderl S; Giles F; Thomas D; Cortes J; O'Brien S; Davis J; Kantarjian HM; Estey E
    Haematologica; 2002 Aug; 87(8):804-7. PubMed ID: 12161355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of acute myeloid leukemia in elderly patients: the influence of maintenance therapy (BGM 84 protocol).
    Montastruc M; Reiffers J; Stoppa AM; Sotto JJ; Corront B; Marit G; Maraninchi D; Michallet M; Gastaut JA; Broustet A
    Nouv Rev Fr Hematol (1978); 1990; 32(2):147-52. PubMed ID: 2198531
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
    Lemez P; Vítek A; Michalová K; Zemanová Z; Lukásová M
    Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
    Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
    Haematologica; 1997; 82(5 Suppl):19-22. PubMed ID: 9402749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia.
    Berman E; Raymond V; Daghestani A; Arlin ZA; Gee TS; Kempin S; Hancock C; Williams L; Stevens YW; Clarkson BD
    Cancer Res; 1989 Jan; 49(2):477-81. PubMed ID: 2910465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
    Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
    Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute nonlymphocytic leukemia in the elderly: results of a retrospective study.
    Latagliata R; Sgadari C; Pisani F; Falconi M; Spadea A; Vegna ML; Petti MC
    Haematologica; 1989; 74(2):167-71. PubMed ID: 2501170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Results of induction treatment with idarubicin for acute nonlymphoblastic leukemia in adults].
    Hołowiecki J; Krzemień S; Rudzka E; Krawczyk M; Wojnar J; Hołowiecka B; Wacławik A; Wojciechowska M; Kachel L; Cedrych I
    Acta Haematol Pol; 1994; 25(3):221-30. PubMed ID: 7992594
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
    Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
    Tamura K
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia].
    Nagata K; Abe Y; Hatanaka T; Ito T; Saito M; Ono Y; Kamiya O; Ohara K
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):231-6. PubMed ID: 8311494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.